TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06318169: A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Sponsor: Hoffmann-La Roche · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 1350 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$565,728

Rescue Site Savings

+$377,152

Unlock Full NCT06318169 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06318169 Rescue Dossier →